Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $9.87 million for the quarter.
Capricor Therapeutics Stock Performance
Shares of CAPR traded up $1.00 during mid-day trading on Friday, reaching $15.38. The stock had a trading volume of 1,468,504 shares, compared to its average volume of 948,036. The firm has a market cap of $699.33 million, a price-to-earnings ratio of -14.51 and a beta of 4.08. The business has a fifty day moving average of $14.42 and a 200 day moving average of $13.73. Capricor Therapeutics has a 12 month low of $3.52 and a 12 month high of $23.40.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on CAPR. Cantor Fitzgerald boosted their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, November 14th. HC Wainwright reaffirmed a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Thursday, January 2nd. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $34.50.
View Our Latest Analysis on Capricor Therapeutics
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
